0:00

Role of FDG PETT in lymphoma in response to therapy.

0:07

Our role as imagers in response to therapy in patients

0:10

with lymphoma is to evaluate the changes in intensity

0:15

of tracer uptake

0:17

or FDG in the areas of disease, as well

0:20

as e evaluate areas of new disease, if there are any.

0:25

There's a scale that we usually use

0:27

and it's called DVL score,

0:30

and this is an internationally recommended scale

0:33

for reporting based on clinical trials.

0:37

This can be used for Hodgkin's lymphoma

0:40

and certain types of non-Hodgkin's lymphoma.

0:44

For example, diffuse large B-cell lymphoma, marginal zone

0:49

lymphoma, C-L-L-S-L-L,

0:54

and mycosis fungoides for instance.

0:57

There are some that have a separate criteria which will not

1:01

be covered in these, but essentially would be those

1:04

that are primarily extra nodal lymphoma

1:07

or cutaneous lymphoma.

1:09

So the scale that we use is essentially comparing the degree

1:13

of uptake in the disease to compared

1:17

to the degree of uptake in the mediastinum or liver.

1:22

We use SUV max.

1:25

Uh, so whenever we apply our volume of interest,

1:29

we'll be using that number as a quantitative measurement,

1:33

but the scale itself is visual also

1:37

as a response criteria.

1:39

There's the clinical lugano criteria, not the staging,

1:44

but this would be the response.

1:47

And these are classified as complete response, partial

1:52

response, a stable disease in progression of disease.

1:57

So whenever we say a double score of one

2:02

through three, we are telling the clinician

2:07

that this is a complete response,

2:09

so it's clinically favorable.

2:11

Whereas if the patient has a scale of they be four

2:15

or five, it would be either partial response

2:19

or stable disease would be, depending on the case, new areas

2:24

of disease would fall into the progression

2:27

of disease category.

2:29

So these are how the clinical criteria

2:31

and the imaging criteria merge,

2:35

and it's important to keep in mind when you're reading these

2:37

cases.

Role of FDG PET/CT Imaging in Lymphoma: Response to Therapy

HIDE

Prev Next

Interactive Transcript

Pro Tip: Click on a word in the transcript to jump to that point in the video

0:00

Role of FDG PETT in lymphoma in response to therapy.

0:07

Our role as imagers in response to therapy in patients

0:10

with lymphoma is to evaluate the changes in intensity

0:15

of tracer uptake

0:17

or FDG in the areas of disease, as well

0:20

as e evaluate areas of new disease, if there are any.

0:25

There's a scale that we usually use

0:27

and it's called DVL score,

0:30

and this is an internationally recommended scale

0:33

for reporting based on clinical trials.

0:37

This can be used for Hodgkin's lymphoma

0:40

and certain types of non-Hodgkin's lymphoma.

0:44

For example, diffuse large B-cell lymphoma, marginal zone

0:49

lymphoma, C-L-L-S-L-L,

0:54

and mycosis fungoides for instance.

0:57

There are some that have a separate criteria which will not

1:01

be covered in these, but essentially would be those

1:04

that are primarily extra nodal lymphoma

1:07

or cutaneous lymphoma.

1:09

So the scale that we use is essentially comparing the degree

1:13

of uptake in the disease to compared

1:17

to the degree of uptake in the mediastinum or liver.

1:22

We use SUV max.

1:25

Uh, so whenever we apply our volume of interest,

1:29

we'll be using that number as a quantitative measurement,

1:33

but the scale itself is visual also

1:37

as a response criteria.

1:39

There's the clinical lugano criteria, not the staging,

1:44

but this would be the response.

1:47

And these are classified as complete response, partial

1:52

response, a stable disease in progression of disease.

1:57

So whenever we say a double score of one

2:02

through three, we are telling the clinician

2:07

that this is a complete response,

2:09

so it's clinically favorable.

2:11

Whereas if the patient has a scale of they be four

2:15

or five, it would be either partial response

2:19

or stable disease would be, depending on the case, new areas

2:24

of disease would fall into the progression

2:27

of disease category.

2:29

So these are how the clinical criteria

2:31

and the imaging criteria merge,

2:35

and it's important to keep in mind when you're reading these

2:37

cases.

Report

Faculty

Elisa Franquet Elia, MD

Assistant Professor of Radiology

UMass Chan Medical School

Lesson

Introduction to PET/CT Imaging

Lesson

FDG Use in PET/CT

Lesson

FDG: Common Pitfalls and Benign Lesions

Lesson

FDG Use in Hematologic Malignancies

Lesson

FDG Use in Lung Cancer

Lesson

FDG Use in Head & Neck Cancer

Lesson

FDG Use in Breast Cancer

Lesson

FDG Use in Immunotherapy

Lesson

DOTATATE Use in PET/CT

Lesson

DOTATATE and FDG Use in Neuroendocrine Tumors

Lesson

PSMA Use in PET/CT

Lesson

PSMA Use in Prostate Cancer

Role of FDG PET/CT Imaging in Lymphoma: Response to Therapy